5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Akums Drugs & Pharmaceuticals Ltd.

•
akums.inBSE: 544222NSE: AKUMS
Market Cap₹ 12,217 Cr.
Current Price
High / Low₹ 797 / 409
Stock P/E41.9
Book Value₹ 217
Price to Book2.15
Dividend Yield0.39 %
ROCE14.8 %
ROE8.1 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • CDMO: 80.1% • Branded & Generic Formulations: 12.7% • API: 5.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Latest quarter profit grew 56.1% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 3.57x)
  • Company generates healthy free cash flow
  • Institutional investors have been accumulating - FII+DII up 2.3pp

CONS

  • Recent results are weak - TTM profit is down 31.7% versus prior year
  • A large part of profit comes from other income (33.7% of PBT)
  • Promoter holding has decreased over last 2 years: -9.6pp
  • Company has a low return on equity of 8.8% over last 3 years
  • Company has a low return on capital employed of 11.0%

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.AKUMS776.2041.8812216.920.39100.9856.111166.6313.9314.7714.97
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
9701,1811,0839441,0191,0331,0101,0561,0241,0181,1601,1581,167
1,0951,0299899418919128899628959231,0131,0061,058
Operating Profit-1251529331281211219412994147152109
OPM %-12.92%12.85%8.63%0.32%12.56%11.73%12.01%8.90%12.59%9.29%12.66%13.10%9.33%
8-21101071719262732163430
Interest121412121312552323242425
Depreciation30303234343545403738404041
Profit before Tax-1598759-33879291759666100121139
Tax %-18.03%62.48%-228.95%-20.04%30.03%27.23%27.17%-99.11%32.37%34.99%32.03%32.89%27.48%
Net Profit000061676615065436881101
-13.162.2213.21-2.894.214.374.269.644.152.664.335.536.53

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
1,8571,5522,0082,4142,7233,6723,6554,1784,1184,3594,502
1,6631,3531,8262,2402,4313,7643,3614,0553,6583,8374,000
Operating Profit195199182174291-92294123461522502
OPM %10.48%12.85%9.08%7.21%10.69%-2.50%8.04%2.94%11.18%11.98%11.15%
9152226-431016873109112
Interest161323207174651359496
Depreciation465256677095113126153155159
Profit before Tax143150126114172-193150-45345382426
Tax %32.99%39.54%45.99%61.65%28.34%-29.85%34.92%101.74%0.43%32.90%31.24%
Net Profit96906844123-251981344256293
EPS813.00777.00579.00357.0317.26-17.656.63-0.2822.0916.67—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%18.00%—

COMPOUNDED SALES GROWTH

10 Years:
10%
5 Years:
10%
3 Years:
6%

COMPOUNDED PROFIT GROWTH

10 Years:
15%
5 Years:
16%
3 Years:
39%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
69%

RETURN ON EQUITY

10 Years:
6%
5 Years:
2%
3 Years:
9%
Last Year:
8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Jul 3

₹ 0.50

Rs.1.0000 per share(50%)Final Dividend

2026

Jul 3

₹ 1

Rs.2.0000 per share(100%)Special Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital111111429293131
Minority Interest212935-2236111718
7107948557218846086896813,0163,283
1891702386997361,4581,6511,9101151,028
Trade Payables147244210423341590567532643602
13215219519418837829323184315
Total Liabilities1,2001,3891,5352,0372,1523,0503,2353,3933,9055,276
6036496526449041,0211,0971,1911,3971,456
Capital Work in Progress000571731103195160177
012962000000
244295268398430722730630681756
0000000834770797
Cash & Bank71821147681031502775761,681
3464155857847141,1731,155266321411
Total Assets1,2001,3891,5352,0372,1523,0503,2353,3933,9055,276

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
1942042877179872744984651,181
Cash from Investing-128-111-49-190-109-235-305-330-548-930
Cash from Financing-34-3575233-95236125-1087334
-711371-7033-460-10285

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Mar 2023Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
84.9175.2675.2675.2675.2675.2675.2675.2675.26
0.007.346.365.774.242.271.141.381.91
0.007.256.717.398.859.2814.4114.3613.44
Government0.000.000.000.000.000.000.000.000.00
15.0910.1611.6611.5811.6613.199.199.029.39

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-03
General Updates

2026-09-03 - Intimation of ESG Rating

2026-08-25
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-25 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-24
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-24 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about an Update on schedule of the Investors/ Analysts Meet to be held on August 25, 2026

2026-08-13
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-13 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-13
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-13 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript

2026-08-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Link of Recording

2026-08-10
Copy of Newspaper Publication

2026-08-10 - Copy of Newspaper Publication

2026-08-10
Monitoring Agency Report

2026-08-10 - Monitoring Agency Report for the quarter ended June 30, 2026

News

Recent coverage and analyst commentary for AKUMS

Loading news…

🤖

AI Stock Analyst

Akums Drugs & Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login